Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome

NCT02243579 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02243579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2014
Completion date
April 1, 2019
Enrollment
24 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent mycosis fungoides and sezary syndrome, refractory mycosis fungoides and sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v7, stage iia mycosis fungoides and sezary syndrome ajcc v7, stage iib mycosis fungoides and sezary syndrome ajcc v7, stage iiia mycosis fungoides and sezary syndrome ajcc v7, stage iiib mycosis fungoides and sezary syndrome ajcc v7, stage iva mycosis fungoides and sezary syndrome ajcc v7, stage ivb mycosis fungoides and sezary syndrome ajcc v7